Genentech Builds Tarceva Inventory Following Iressa's Failed Trial

Genentech has been building inventory for its non-small cell lung cancer agent Tarceva (erlotinib) following AstraZeneca's announcement that Iressa (gefitinib) failed to show a statistically significant survival benefit